The special practice for liver diseases in the heart of Munich
for liver diseases
- Benefit from an experienced team of experts
- Learn to appreciate the optimal individual treatment
- The most modern diagnostic methods give you security
- We are always on the cutting edge of research
The special practice for liver diseases combines
the private touch and the organizational advantages of
a small practice with the standards of a university facility.
in the heart
In our practice with focus on the liver we want that our patients draw the best possible benefit from our expert knowledge in chronic liver diseases.
Dedicated to prevention, diagnosis and treatment of the various forms of liver diseases the small liver center right in the heart of Munich is working with all modern tools.
In a practice for general medicine or gastroenterology patients with liver disorders represent only a small part; hepatology (the science of liver disease) has made a huge progress recently and at the same time has become increasingly more complex. To keep up with knowledge in that field is very laborious and at the final end almost impossible in a non-specialized practice.
Our aim is to give our patients access to the latest
developments in hepatology by cooperating with university
facilities and at the same time to offer personal care.
As an independent practice we are free to work
together with the best specialists from all disciplines,
independently of where they work.
- to prevent
the development of liver disease
through prophylactic measures;
- to diagnose liver disorders before
irreversible damage has occurred;
- to prevent the progression of
an existing liver disease;
- to treat liver disease according to up-to-date
guidelines and to improve the quality of those affected.
Maria-Christina Jung began her education at the Institute for Immunology at the Ludwig-Maximilians-Universität, Munich, Gottfried Fischer at the Institute of Clinical Pharmacology and Visceral Research at the University of Berne. Reinhart Zachoval began his medical training at the Max von Pettenkofer Institute in Munich, went then to Boston at the Massachusetts General Hospital and got his further education in internal medicine and gastroenterology at the Grosshadern Medical Center of the Ludwig Maximilians University in Munich.
All three members of the team have worked together successfully for many years.
Maria-Christina Jung has focused for many years on the question of why an infection with
liver damaging viruses (hepatitis B, hepatitis C) can become chronic, and has, through numerous
scientific studies, contributed to a better understanding of the underlying mechanisms of viral
infection. In addition, she is taking part in numerous clinical studies to improve the treatment of
hepatitis B and hepatitis C and investigates the effect of new therapeutic approaches on the
human immune system.
Reinhart Zachoval was the principal investigator of numerous studies for the treatment of chronic hepatitis B and C at Grosshadern Medical Center and was the head of a large outpatient department there for many years taking care of more than 3000 liver patients per year (including liver transplant recipients).
Specialization in the field of liver
- through the day-to-day treatment of people suffering from serious liver disease
- through special technical examination like duplex sonography and liver stiffness measurements by ultrasound ("elastography")
- through the application of special endoscopic and imaging techniques ( in collaboration with others)
- through assessment of potential liver transplantation candidates and follow-up long term care after the operation
How can one recognize liver disease and
what can be done to prevent it?
Some liver diseases can be prevented (for instance by immunization or by avoiding toxic substances), and in others an early diagnosis is important for an effective treatment. An advanced chronic liver disease often becomes obvious by pronounced tiredness and weakness, by accumulation of fluid in the peritoneal cavity ("ascites") by massive hemorrhage from oesophageal varices or from mental disturbances up to coma.
However, an early diagnosis can be difficult because many liver diseases develop in the absence of unambiguous symptoms. Even people who feel completely healthy may suffer from liver disease. Through our special knowledge and the application of the most up-to-date techniques, we are especially qualified to make a balanced assessment and to decide on the appropriate (and sometimes life-saving) treatment at the earliest possible time point.
Treatment: methods and techniques
There are only very few liver diseases that can’t be beneficially influenced through timely therapy. Therefore, complementary to our fundamental laboratory and technical examinations, we also perform the completely painless ultrasound elastography procedure. With this technology the firmness of the liver is measured in order to detect the presence of a liver conversion — a so-called fibrosis. The firmer the liver, the more advanced the fibrosis and therefore the greater the risk for developing liver cirrhosis.
Until now, such a diagnosis was only possible through the removal of liver tissue and a subsequent biopsy, which is painful and carries a risk of hemorrhage and is therefore declined by many patients. In contrast, the ultrasound elastography can be carried out as an outpatient procedure and can be repeated as often as required — for a precise diagnosis, but also to document the success of a therapy.
Consultation by arrangement
by phone or online via Doctolib.
How to reach us:
By public transportation/MVV
U1, U2, U3, U6 or Bus 152, Tram 16, 17, 18, 27
Parking garage at Oberanger or Herzog-Wilhelm Straße
Non-invasive assessment of liver alterations in Senning and Mustard patients
Nagdyman N, Mebus S, Kügel J, , Clevert DA, Braun SL, Haverkämper G, Opgen-Rhein B, Berger F, Horster S, Schoetzau J, Salvador CP, Bauer U, Hess J, Ewert P, Kaemmerer H.
In: Cardiovascular Diagnosis and Therapy, 2019 Oct; 9(Suppl 2):S198-S208. DOI:10.21037/cdt.2019.07.10
Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections
Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, , Schott E, Fülöp B, Schlosser B, Berg T, van Bömmel F.
In: European Journal of Gastroenterology & Hepatology, 2019 Jul; 31(7):845-852. DOI:10.1097/MEG.0000000000001351
Intrahepatic diffuse periportal enhancement patterns on hepatobiliary phase gadoxetate disodium-enhanced liver MR images: Do they correspond to periportal hyperintense patterns on T2-weighted images?
Onishi H, Theisen D, , Reiser MF, Zech CJ.
In: Medicine, 2019 Mar; 98(11) DOI:10.1097/MD.0000000000014784
Non-cardiac comorbidities in adults with inherited and congenital heart disease: report from a single center experience of more than 800 consecutive patients
Neidenbach RC, Lummert E, Vigl M, , Fischereder M, Engelhardt A, Pujol C, Oberhoffer R, Nagdyman N, Ewert P, Hauser M, Kaemmerer H.
In: Cardiovascular Diagnosis and Therapy, 2018 Aug; 8(4):423-431. DOI:10.21037/cdt.2018.03.11.
Non-invasive assessment of liver changes in Eisenmenger patients
Mebus S, Nagdyman N, Kügel J, , Braun SL, Haverkämper G, Opgen-Rhein B, Berger F, Horster S, Schoetzau J, Salvador CP, Bauer U, Hess J, Ewert P, Kaemmerer H.
In: International Journal of Cardiology, 2017 Dec; 249:140-144. DOI:10.1016/j.ijcard.2017.07.029
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity
Deterding K, Grüner N, Buggisch P, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Grohennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, , Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H, Wiegand J; Hep-Net Acute HCV-III Study Group.
In: European Journal of Gastroenterology & Hepatology, 2016 Feb; 28(2):187-92. DOI:10.1097/MEG.0000000000000517
Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort
Schnitzler F, Friedrich M, Stallhofer J, Schönermarck U, Fischereder M, Habicht A, Karbalai N, Wolf C, Angelberger M, Olszak T, Beigel F, Tillack C, Göke B, , Denk G, Guba M, Rust C, Grüner N, Brand S.
In: PLoS One. 2015 Aug;10(8):e0135807. DOI:10.1371/journal.pone.0135807
Point Shear Wave Elastography by Acoustic Radiation Force Impulse Quantification in Comparison to Transient Elastography for the Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multicenter Study
Friedrich-Rust M, Lupsor M, de Knegt R, Dries V, Buggisch P, Gebel M, Maier B, Herrmann E, Sagir A, , Shi Y, Schneider MD, Badea R, Rifai K, Poynard T, Zeuzem S, Sarrazin C.
In: Ultraschall in der Medizin, 2015 Jun; 36(3):239-47. DOI:10.1055/s-0034-1398987
Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction.
Kurktschiev PD, Raziorrouh B, Schraut W, Backmund M, Wächtler M, Wendtner CM, Bengsch B, Thimme R, Denk G, , Dick A, Spannagl M, Haas J, Diepolder HM, , Gruener NH
In: The Journal of Experimental Medicine, 2014 Sep; 211(10):2047-59
Influence of hepatitis C virus infection and high virus serum load on biliary complications in liver transplantation
Horster S, Bäuerlein FJ, Mandel P, Raziorrouh B, Hopf C, Stemmler HJ, Guba M, Angele M, Stangl M, Rentsch M, Frey L, Kaspar M, Kaczmarek I, Eberle J, Nickel T, Gruener N, , Diepolder H
In: Transplant Infectious Disease, 2013 Jun; 15(3):306-13
Therapy of hepatocellular carcinoma before liver transplantation
Guba M, Angele M, Rentsch M, Jauch KW, , Kolligs F, Gerbes A, Bruns CJ
In: Der Chirurg, 2013 May; 84(5):385-90
Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease
Rath T, Hage L, Kügler M, Menendez Menendez K, , Naehrlich L, Schulz R, Roderfeld M, Roeb E
In: PLOS ONE. 2013; 8(3):e58955
Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation?
Pratschke S, Meimarakis G, Bruns CJ, Kaspar M, Prix N, , Guba M, Jauch KW, Loehe F, Angele MK
In: Transplant International, 2013 Jan; 26(1):90-8
YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis
Rath T, Roderfeld M, Güler C, Wenzel C, Graf J, Beitinger F, Roeb E,
In: Scandinavian Journal of Gastroenterology, 2011 Nov; 46(11):1369-80
Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection.
Raziorrouh B, Ulsenheimer A, Schraut W, Heeg M, Kurktschiev P, Zachoval R, , Thimme R, Neumann-Haefelin C, Horster S, Wächtler M, Spannagl M, Haas J, Diepolder HM, Grüner NH
In: Gastroenterology, 2011 Oct; 141(4):1422-31
Hepatitis A - combined prolonged biphasic and cholestatic course of disease
Schmidt L, , Diepolder H, Kolligs FT
In: Deutsche medizinische Wochenschrift, 2011 May; 136(20):1057-9
Arterial blood flow predicts graft survival in liver transplant patients
Pratschke S, Meimarakis G, Mayr S, Graeb C, Rentsch M, , Bruns CJ, Kleespies A, Jauch KW, Loehe F, Angele MK
In: Liver Transplantation, 2011 Apr; 17(4):436-45
The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function.
Raziorrouh B, Gerlach T, Schraut W, Grüner NH, Ulsenheimer A, , Wächtler M, Spannagl M, Haas J, Diepolder HM,
In: Hepatology, 2010 Dec; 52(6):1934-47
Comparing acoustic radiation force impulse imaging to transient elastography to assess liver stiffness in healthy volunteers with and without valsalva manoeuvre
Horster S, Mandel P, , Clevert DA
In: Clinical Hemorheology and Microcirculation, 2010; 46(2-3):159-68
FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C.
Heeg MH, Ulsenheimer A, Grüner NH, , , Gerlach JT, Raziorrouh B, Schraut W, Horster S, Kauke T, Spannagl M, Diepolder HM.
In: Gastroenterology, 2009 Oct; 137(4):1280-8
Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection.
Vogel M, Deterding K, Wiegand J, Grüner NH, Baumgarten A, , Manns MP, Wedemeyer H, Rockstroh JK, German Hepatitis Group, Hep-Net
In: Clinical Infectious Diseases, 2009 Jul; 49(2):317-9; author reply 319
The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection.
Deterding K, Wiegand J, Grüner N, Hahn A, Jäckel E, , Buggisch P, Galle P, Berg T, Hinrichsen H, Potthoff A, Zeuzem S, Cornberg M, Manns M, Wedemeyer H
In: Zeitschrift für Gastroenterology, 2009 Jun; 47(6):531-40
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.
Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S,
In: Gastroenterology, 2009 Jun; 136(7):2169-2179
Late appearance of hepatitis C virus RNA after needlestick injury: necessity for a more intensive follow-up.
Gruener NH, Heeg M, Obermeier M, Ulsenheimer A, Raziorrouh B, Diepolder H, ,
In: Infection Control and Hospital Epidemiology, 2009 Mar; 30(3):299-300
Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B, , Schirren CA, Loehe F, Thiel M, Nitschko H, Diepolder H, Ulsenheimer A, Heeg M, , Gruener NH
In: European Journal of Gastroenterology & Hepatology, 2008 Aug; 20(8):778-83
Two consecutive episodes of acute hepatitis C with different genotypes in a hemodialysis patient responsive to PEG-interferon monotherapy
Lederer S, , Hasholzner U, Schiffl H
In: Clinical Nephrology, 2008 Apr; 69(4):313-6
Recurrence of hepatitis C virus during leucocytopenia and spontaneous clearance after recovery from cytopenia: a case report.
Gruener NH, Raziorrouh B,
In: Journal of Medical Case Reports, 2007 Dec; 1(1):169
Orellanus syndrome: a rare cause of acute renal failure.
Wessely M, Schönermarck U, Raziorrouh B, , Samtleben W
In: Deutsche medizinische Wochenschrift, 2007 Sep; 132(37):1880-2
Characterization of sequence variations in immunodominant regions of the HBV-nucleocapsid protein as a prerequisite for the development of an epitope-based vaccine.
Gruener NH, Gerlach TJ, Ulsenheimer A, Diepolder HM, Wierenga E, , Heeg M, Pape GR,
In: Vaccine, 2007 Jun; 25(26):4960-6
Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
Nevens F, Zuckerman JN, Burroughs AK, , Bayas JM, Kallinowski B, Rivas EF, Duvoux C, Neuhaus P, Saliba F, Buti M, Zarski JP, Pons F, Vanlemmens C, Hamtiaux V, Stoffel M
In: Liver Transplantation, 2006 Oct; 12(10):1489-95
Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins.
Gerlach JT, Ulsenheimer A, Grüner NH, , Schraut W, Schirren CA, Heeg M, Scholz S, Witter K, Zahn R, Vogler A, , Pape GR, Diepolder HM
In: Journal of Virology, 2005 Oct; 79(19):12425-33